Why the study?
Right ventricle-pulmonary artery coupling is prognostically important in valvular heart disease, but its association with clinical endpoints after intervention for AS, MR, and TR needed quantification.
Does reduced RV-PA coupling (TAPSE/PASP) predict all-cause mortality and MACE in patients undergoing valve interventions for AS, MR, and TR?
Meta-Analysis (n=12,992)
Yes
Does reduced RV-PA coupling (TAPSE/PASP) predict all-cause mortality and MACE in patients undergoing valve interventions for AS, MR, and TR?
Reduced RV-PA coupling (TAPSE/PASP) is an independent predictor of all-cause mortality and MACE after interventions for aortic stenosis and mitral regurgitation, with specific thresholds identified for risk stratification.
Answers are grounded in this paper and cite their sources.
Supports TAPSE/PASP integration into post-valve risk stratification; extends prognostic evidence across AS and MR interventions.
BACKGROUND: Right ventricle-pulmonary artery (RV-PA) coupling is prognostically important in valvular heart disease. OBJECTIVES: The authors performed a systematic review and meta-analysis to quantify the association of RV-PA coupling with clinical endpoints after intervention for aortic stenosis (AS), mitral regurgitation (MR), and tricuspid regurgitation (TR). METHODS: The primary outcome was all-cause mortality, and the secondary outcome was a composite of major adverse cardiovascular events (MACE). A random-effects model was used to compute pooled effect estimates, and summary receiver-operating characteristic curves identified optimal RV-PA thresholds. RESULTS: In total, 30 interventional studies (N = 12,992) met eligibility criteria, including 14 AS (n = 6,100), 12 MR (n = 5,032), and 4 TR (n = 1,860) studies. Tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (PASP) was the most studied RV-PA coupling index. Reduced TAPSE/PASP was independently associated with all-cause mortality (AS adjusted HR: 1.69 [95% CI: 1.30-2.20]; MR adjusted HR: 1.94 [95% CI: 1.40-2.69]; P < 0.001) and the composite MACE (AS adjusted HR: 1.60 [95% CI: 1.29-2.00]; MR adjusted HR: 2.01 [95% CI: 1.54-2.62]; P < 0.001). There were significant nonlinear associations between TAPSE/PASP and adverse outcomes in AS and MR (P < 0.001). There were insufficient data to estimate a pooled effect-size in TR. Optimal TAPSE/PASP thresholds to predict all-cause mortality were ≤0.51 mm/mm Hg for AS interventions, ≤0.33 mm/mm Hg for MR interventions and ≤0.44 mm/mm Hg for TR interventions. CONCLUSIONS: TAPSE/PASP is an independent predictor of outcomes after interventions for AS and MR. The disease-specific TAPSE/PASP cutoffs could be integrated into risk-stratification models to better predict mortality before valve interventions and improve patient selection.
No takes yet. Share an insight, caveat, or question.
Androshchuk et al. (2025) conducted a meta-analysis in Severe native aortic stenosis (AS), mitral regurgitation (MR), or tricuspid regurgitation (TR) (n=12,992). Reduced TAPSE/PASP (RV-PA uncoupling) vs. Preserved TAPSE/PASP (RV-PA coupling) was evaluated on All-cause mortality (Aortic Stenosis cohort) (HR 1.69, 95% CI 1.30-2.20, p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: